"Telomerase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An essential ribonucleoprotein reverse transcriptase that adds telomeric DNA to the ends of eukaryotic CHROMOSOMES.
| Descriptor ID |
D019098
|
| MeSH Number(s) |
D08.811.913.696.445.308.300.750.750 D12.776.157.687.613 D12.776.157.725.500.921 D12.776.660.720.613 D12.776.664.962.500.921
|
| Concept/Terms |
Telomerase- Telomerase
- Telomerase Reverse Transcriptase
- Reverse Transcriptase, Telomerase
- Transcriptase, Telomerase Reverse
Telomerase Catalytic Subunit- Telomerase Catalytic Subunit
- Catalytic Subunit, Telomerase
- Subunit, Telomerase Catalytic
- Telomerase Reverse Transcriptase Catalytic Subunit
|
Below are MeSH descriptors whose meaning is more general than "Telomerase".
Below are MeSH descriptors whose meaning is more specific than "Telomerase".
This graph shows the total number of publications written about "Telomerase" by people in this website by year, and whether "Telomerase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 1 | 2 |
| 2004 | 3 | 1 | 4 |
| 2006 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2011 | 2 | 1 | 3 |
| 2012 | 0 | 1 | 1 |
| 2013 | 2 | 3 | 5 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2017 | 4 | 1 | 5 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Telomerase" by people in Profiles.
-
Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Sci Rep. 2021 09 09; 11(1):18009.
-
TERT Gene Fusions Characterize a Subset of Metastatic Leydig Cell Tumors. Clin Genitourin Cancer. 2021 08; 19(4):333-338.
-
Loss of 5-Hydroxymethylcytosine is an Epigenetic Hallmark of Thyroid Carcinomas with TERT Promoter Mutations. Endocr Pathol. 2020 Dec; 31(4):359-366.
-
The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis. BMC Cancer. 2020 Sep 21; 20(1):897.
-
Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019 07 15; 200(2):199-208.
-
A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma. Oncogene. 2018 07; 37(27):3740-3752.
-
TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data. Crit Rev Oncol Hematol. 2017 Dec; 120:1-9.
-
Role of molecular markers to predict distant metastasis in papillary thyroid carcinoma: Promising value of TERT promoter mutations and insignificant role of BRAF mutations-a meta-analysis. Tumour Biol. 2017 Oct; 39(10):1010428317713913.
-
Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clin Endocrinol (Oxf). 2017 Nov; 87(5):411-417.
-
A common intronic variant of PARP1 confers melanoma risk and mediates melanocyte growth via regulation of MITF. Nat Genet. 2017 Sep; 49(9):1326-1335.